Option Investor
Newsletter

On The "Watch" List - MYGN

HAVING TROUBLE PRINTING?
Printer friendly version
Myriad Genetics (NASDAQ:MYGN) traded below our "comfort level"
today as investors unloaded the stock in large blocks, despite any
(public) news to explain the downside activity. At mid-session, the
issue was nearly 5% lower on volume that exceeded the daily average.

This position was one of our more speculative plays, thus we received
a fairly large premium ($0.45) for the sold option. Conservative traders
can close the position and remove the obligation to buy the stock for
minimal expense ($5.00 - $10.00 net; per contract). Although the play
is currently profitable, a conservative approach may be the best tactic
in light of today's "unexplained" activity.

Option Writers Newsletter Archives